Nucleic Acid Based Gene Therapy Market

USD 31,646 is the average a treated patient-year of nucleic acid based gene therapy realised in 2025, a blend of USD 3,900 twice-yearly inclisiran courses and viral vector gene therapy treatments realising about USD 1.53 million each, most of them one-time adeno-associated virus (AAV) infusions. The nucleic acid based gene therapy market covers marketed medicines that deliver DNA or RNA to silence, splice or replace a faulty gene: small interfering RNA (siRNA), antisense oligonucleotides (ASOs), in vivo viral vector gene therapies and ex vivo gene-modified stem cell therapies. Multiply 336,600 treated patient-years by that USD 31,646 and the 2025 total comes to USD 10.65 billion. Douglas Insights projects USD 29.45 billion by 2035, a 10.70% revenue CAGR built from 14.6% patient-year growth and a price leg of minus 3.4%. One-time dosing widened on 24 November 2025, when the US Food and Drug Administration (FDA) approved Itvisma, an intrathecal onasemnogene abeparvovec dose for spinal muscular atrophy (SMA) patients aged two and older. The study is part of the Douglas Insights pharmaceuticals coverage and is built on the published research methodology.

Which molecules are in scope, from siRNA duplexes and morpholinos to AAV capsids?

Four nucleic acid based gene therapy classes are in scope, worth USD 10.65 billion across 336,600 treated patient-years in 2025. They are siRNA, ASOs including phosphorodiamidate morpholino oligomers (PMOs), in vivo viral vectors and ex vivo gene-modified stem cells.

Our count holds 39 approved products. siRNA duplexes such as vutrisiran and inclisiran silence a messenger RNA in the liver; ASOs such as nusinersen switch splicing in motor neurons. Viral vectors carry a working DNA copy into the patient; ex vivo products edit or transduce hematopoietic stem cells (HSCs) outside the body. Messenger RNA vaccines, oncolytic viruses and chimeric antigen receptor T-cell (CAR-T) therapies sit outside the boundary, because they work as vaccines, tumour-killing viruses or engineered immune cells rather than as gene silencing or replacement. Revenue is counted at manufacturer net sales, so the royalty Alnylam books on inclisiran is not counted twice.

How much does a patient-year of inclisiran, nusinersen or an AAV infusion cost payers?

Payers spent an average USD 31,646 per treated patient-year on nucleic acid based gene therapy in 2025. The spread runs from about USD 3,900 for cholesterol siRNA to roughly USD 2.55 million per ex vivo stem cell treatment, about a 650-fold gap.

Douglas Insights estimates these realised bands from 2025 net sales divided by modelled treated patients, because no manufacturer discloses net price per patient. Inclisiran is the volume anchor: 2 injections a year, priced like a specialty cardiovascular drug, carrying 91.3% of all patient-years and 11.2% of value. Rare-disease siRNA for transthyretin amyloidosis (ATTR), porphyria and hyperoxaluria realises about 74 times more per patient-year. Gene therapy paid once is priced on a lifetime of avoided care. A vector treatment at USD 1.53 million equals about 8 years of ASO maintenance at the USD 190,800 average.

The blended average falls 3.4% a year to about USD 22,392 by 2035. That decline is a mix effect, not discounting: cholesterol and cardiomyopathy patients at low per-year prices outgrow one-time infusions. Cheap volume wins. Value still compounds.

Which modality makes the money: siRNA, antisense oligonucleotides or viral vectors?

siRNA therapies make the most money in nucleic acid based gene therapy, USD 4.26 billion or 40.0% of 2025 value, because vutrisiran and inclisiran reached large adult populations that one-time gene replacement cannot reach.

Small interfering RNA (siRNA) therapies hold USD 4.26 billion, 40.0% of value, and grow 13.58% a year to USD 15.23 billion, since twice-yearly or quarterly dosing suits chronic cardiology and ATTR care. Antisense oligonucleotide (ASO) therapies earn USD 3.20 billion, a 30.1% share, carried by nusinersen and the Duchenne PMOs; they grow only 6.18% because SMA demand shifts toward one-time vectors. In vivo viral vector gene therapies take USD 2.93 billion, 27.5% of value, and reach USD 6.99 billion at 9.07% a year, led by onasemnogene abeparvovec, delandistrogene moxeparvovec and the topical vector beremagene geperpavec. Ex vivo gene-modified stem cell therapies are the fastest segment at 17.35% a year, from USD 254.9 million to USD 1.26 billion, because sickle cell and beta-thalassemia treatment centres are still building collection and conditioning capacity.

Segment values for 2035 sum to USD 29.31 billion, within 0.5% of the USD 29.45 billion headline. Manufacturing capacity behind the vector segments is sized in the Cell and Gene Therapy CDMO Services Market report.

Why are cholesterol and cardiomyopathy patients the growth engine for gene-silencing therapy?

Cardiovascular patients supply 11.4 of the 14.6 points of annual patient-year growth in nucleic acid based gene therapy, because LDL cholesterol and ATTR cardiomyopathy (ATTR-CM) populations run into the millions, not thousands.

Cholesterol siRNA adds 7.3 points. Novartis reported Leqvio net sales of USD 1.20 billion for 2025, up 59%, for a twice-yearly injection that lowers low-density lipoprotein cholesterol (LDL-C). Douglas Insights counts about 307,200 inclisiran patient-years in 2025, and every point of penetration in secondary prevention adds tens of thousands more. At USD 3,900 a patient-year, each 100,000 added inclisiran patients adds only USD 390.0 million, which is why patient-years and value diverge. Gene silencing now competes with statins on adherence rather than on biology.

ATTR cardiomyopathy adds 4.1 points. Alnylam reported AMVUTTRA net product revenues of USD 2.31 billion for 2025, up 138%, and guides total TTR revenue of USD 4.4 billion to USD 4.7 billion for 2026. The cardiomyopathy label turned a rare polyneuropathy drug into a heart-failure therapy. Eplontersen, an ASO sold by AstraZeneca, added USD 212.0 million of 2025 sales in the same disease. Patisiran fell 32% to USD 172.8 million as patients moved to quarterly vutrisiran, so the franchise gain is net of switching. Alnylam guides USD 4.9 billion to USD 5.3 billion of total 2026 net product revenue.

Neuromuscular disease adds 1.8 points. The Itvisma approval of 24 November 2025 opened one-time intrathecal gene therapy to SMA patients aged two and older, among about 9,000 people living with SMA in the US. Duchenne muscular dystrophy (DMD) was added to the US Recommended Uniform Screening Panel (RUSP), and Chugai launched delandistrogene moxeparvovec in Japan in February 2026, according to Sarepta. Earlier diagnosis widens the treatable window for both PMOs and vectors.

Rare metabolic and blood disorders add the last 1.4 points. Givosiran grew 21% to USD 308.5 million and lumasiran 15% to USD 191.4 million in 2025, steady growth in acute hepatic porphyria and primary hyperoxaluria. Ionis booked USD 108.0 million of olezarsen sales in its first full year on the market, and ex vivo sickle cell therapies gained a Medicaid payment route through the Cell and Gene Therapy Access Model, with 34 states joining between January 2025 and January 2026. Together the four drivers sum to the 14.6% patient-year leg: 7.3 plus 4.1 plus 1.8 plus 1.4.

Which hurdles slow AAV gene therapy uptake and ex-US launches?

Three restraints remove 2.8 points from nucleic acid based gene therapy patient-year growth in the slower case, cutting the volume leg from 14.6% to 11.8%: vector safety, health technology assessment (HTA) and ex-US price negotiation.

Vector safety costs 1.2 points. The FDA added a boxed warning for serious liver injury to delandistrogene moxeparvovec in November 2025 and removed the non-ambulatory indication, as Sarepta reported. ELEVIDYS revenue fell to USD 110.4 million in the fourth quarter of 2025, against USD 898.7 million for the full year. Every high-dose systemic AAV programme now carries that liver-safety read-across.

HTA and payer review costs 0.9 points. The EU HTA Regulation has applied since 2025, with joint clinical assessments starting with cancer medicines and advanced therapy medicinal products, so each new European gene therapy faces an added evidence step before national pricing. Douglas Insights expects that step to delay European uptake by 6 to 12 months per launch.

Ex-US pricing costs 0.7 points. Krystal Biotech expects German price talks for its topical HSV-1 vector to run through at least the second half of 2026 and French talks through at least 2027, even with over 90 patients prescribed across Germany, France and Japan. Small populations make every country negotiation material for gene therapy revenue.

How many SMA and Duchenne patients can one-time AAV dosing still reach?

Neuromuscular gene therapy earned about USD 4.64 billion in 2025, 43.6% of nucleic acid based gene therapy value, split between chronic ASOs and one-time AAV vectors for SMA and DMD.

Biogen booked USD 1.55 billion of nusinersen revenue in 2025, 59.6% of it outside the US, while Novartis booked USD 1.23 billion for its onasemnogene abeparvovec franchise, up 1%. Sarepta earned USD 965.6 million from three exon-skipping PMOs and USD 898.7 million from its DMD vector. Douglas Insights puts the one-time share of SMA treatment revenue at 44.3% in 2025, and expects it to cross 50% by 2029 as older patients switch from chronic dosing.

One-time dosing has a ceiling. A treated child leaves the revenue pool, so vector income depends on incident births, newborn screening and catch-up of older patients. Intrathecal delivery at a fixed dose removes the weight limit that capped intravenous use, which is why Itvisma matters more for volume than for price. Nucleic acid extraction for SMA and DMD screening is sized in the Magnetic Bead-based Nucleic Acid Extraction Market report.

Who wins patients in nucleic acid gene therapy: Alnylam, Novartis, Sarepta or Biogen?

Alnylam leads nucleic acid based gene therapy with 28.0% of 2025 value, USD 2.99 billion of siRNA product revenue, and the top three hold 68.4% on disclosed net sales.

Shares are Douglas Insights estimates built on each company’s disclosed 2025 product revenue divided by our USD 10.65 billion total. Alnylam’s 2025 results show USD 2.99 billion of net product revenue, up 81%, plus USD 174.0 million of inclisiran royalties that we exclude to avoid double counting. Novartis follows at 22.8% from USD 1.20 billion of inclisiran and USD 1.23 billion of onasemnogene abeparvovec, and its 24 November 2025 Itvisma approval adds an older SMA population to that franchise. Sarepta holds 17.5%, Biogen 15.3% on USD 1.55 billion of nusinersen plus USD 86.9 million of tofersen, and Ionis also earns USD 212.0 million of nusinersen royalties.

Krystal Biotech earned USD 389.1 million at a 94% gross margin. Vertex Pharmaceuticals and Genetix Biotherapeutics supply the ex vivo sickle cell products in the CMS model. CSL, PTC Therapeutics and BioMarin sell smaller AAV products. Aptamer chemistry, a near relative of ASOs, is covered in the Aptamers Market report.

Where is siRNA and AAV therapy revenue booked, and which region grows fastest?

North America books USD 5.54 billion of nucleic acid based gene therapy revenue in 2025, 52.0% of value, because US list prices and early launches of vutrisiran, delandistrogene moxeparvovec and inclisiran concentrate sales there.

North America grows 10.21% a year to USD 14.64 billion, slowing its share to 49.7% as other regions catch up on cardiology siRNA. Europe holds USD 2.95 billion, 27.7% of value, and grows 9.88%, the slowest, because HTA review and national price talks stretch every launch. Asia Pacific is the fastest region at 13.36% a year, rising from USD 1.53 billion to USD 5.36 billion, as Japan adds DMD vector and ATTR-CM patients and larger Asian markets reimburse inclisiran. Latin America reaches USD 983.7 million by 2035 from USD 318.7 million, growing 11.93% a year. Middle East and Africa is the wildcard: USD 316.3 million in 2025, where one national formulary decision on SMA vectors moves the regional total by double digits.

Which FDA, EU HTA and Medicaid rules shape gene therapy launches?

Three rule sets govern nucleic acid based gene therapy revenue in 2026: FDA approvals, EU joint clinical assessment and Medicaid outcomes-based payment. The Medicaid model covers 34 states for sickle cell gene therapy, and the EU process adds one assessment before 27 national price talks.

The FDA list of approved cellular and gene therapy products holds 54 entries; Douglas Insights counts 14 in vivo vector products and 7 ex vivo autotemcel products among them. siRNA and ASO medicines are reviewed as drugs, not biologics, which shortens their manufacturing comparability work. In Europe the HTA Regulation entered into force in 2022 and has applied since 2025 under the European Commission, so one joint clinical assessment now precedes 27 national pricing talks.

The CMS model is the first time the US federal government negotiated outcomes-based agreements with gene therapy manufacturers for state Medicaid agencies. Manufacturers also pay for a defined scope of fertility preservation, since conditioning chemotherapy causes infertility. Douglas Insights expects the model to lift ex vivo treated patients from about 100 in 2025 to roughly 500 by 2035.

What if ATTR cardiomyopathy uptake stalls before 2035 for gene-silencing drugs?

In the base case nucleic acid based gene therapy reaches USD 29.45 billion in 2035 on 14.6% patient-year growth and a minus 3.4% price leg, with patient-years rising to about 1.32 million.

The slower case stalls ATTR-CM switching from older stabilisers and adds AAV liver-safety holds, leaving 2035 at USD 21.38 billion, USD 8.07 billion below base. The faster case adds broad cholesterol siRNA reimbursement in Asia Pacific and strong older-patient uptake after the 24 November 2025 Itvisma approval, lifting nucleic acid based gene therapy to USD 39.21 billion. Patient-years are the lever: one extra point of annual patient-year growth lifts 2035 to USD 32.12 billion, a USD 2.67 billion gain. Published forecasts span about 8.8% to 22.3% a year; our 10.70% falls in the lower half, because several of those studies size a much smaller USD 0.88 billion to USD 2.5 billion base.

Douglas Exclusive: the nucleic acid therapy approval-to-revenue tracker

The tracker is a Douglas Insights model built from 39 approved product entries and 6 company full-year 2025 reports, matching each nucleic acid based gene therapy to its modality, dosing pattern and revenue.

Four products, vutrisiran, nusinersen, onasemnogene abeparvovec and inclisiran, earn USD 6.29 billion, 59.1% of all 2025 value. Three vectors carry USD 2.52 billion, 85.9% of the in vivo segment, so 11 of the 14 vector products share under USD 413 million. Revenue per approved product falls 14.6-fold from siRNA to ex vivo stem cell products.

The finding: in nucleic acid based gene therapy, dosing frequency predicts revenue better than price per dose. Repeat-dose siRNA and ASO medicines earn 2.0 times as much per approved product as vector products, because they keep a patient in the revenue pool every year. The tracker updates each quarter as approvals and company results arrive.

How we rebuild 336,600 nucleic acid therapy patient-years into the 2025 total?

Our methodology multiplies 336,600 treated patient-years by a blended USD 31,646 per patient-year, giving USD 10,652,043,600, written as USD 10.65 billion of nucleic acid based gene therapy revenue for 2025.

Coverage spans 5 regions, 38 countries, 39 approved products and 4 modalities. The model draws on 152 data points: 14 disclosed product revenue lines, 6 company reports, patient counts, dosing schedules and 4 published growth rates. Disclosed revenue for 14 product lines totals USD 9.63 billion, 90.4% of the 2025 total; Douglas Insights estimates the remaining USD 1.02 billion for products whose makers do not split sales.

Three cross-checks follow. A published 2025 estimate of USD 8.63 billion sits 19.0% below ours; most of that gap is scope, since our count includes every approved RNA, oligonucleotide and vector product sold in 2025. Inclisiran grew 59% and vutrisiran 138% in 2025, far above our 10.70% average, so our smooth 2026 figure of USD 11.79 billion is conservative early in the decade. Check the legs: 1.146 multiplied by 0.966 gives 1.1070, the 10.70% revenue CAGR.

Sources

1. Novartis Novartis receives FDA approval for Itvisma (2025)
2. Novartis Novartis full year 2025 results (2026)
3. Alnylam Pharmaceuticals Alnylam fourth quarter and full year 2025 financial results (2026)
4. Sarepta Therapeutics Sarepta fourth quarter and full year 2025 financial results (2026)
5. Biogen Biogen full year 2025 revenue by product (2026)
6. Ionis Pharmaceuticals Ionis fourth quarter and full year 2025 financial results (2026)
7. Krystal Biotech Krystal Biotech fourth quarter and full year 2025 results (2026)
8. Centers for Medicare and Medicaid Services Cell and Gene Therapy Access Model (2026)
9. US Food and Drug Administration Approved cellular and gene therapy products (2026)
10. European Commission Regulation on health technology assessment (2025)